NASDAQ:ABLX - Ablynx Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$52.89 +0.09 (+0.17 %)
(As of 05/22/2018 07:59 AM ET)
Previous Close$52.80
Today's Range$52.67 - $52.97
52-Week Range$17.75 - $55.29
Volume9,775 shs
Average Volume287,167 shs
Market Capitalization$4.07 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Ablynx (NASDAQ:ABLX)

Ablynx logoAblynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

Receive ABLX News and Ratings via Email

Sign-up to receive the latest news and ratings for ABLX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ABLX
CUSIPN/A
PhoneN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares74,720,000

Ablynx (NASDAQ:ABLX) Frequently Asked Questions

What is Ablynx's stock symbol?

Ablynx trades on the NASDAQ under the ticker symbol "ABLX."

What price target have analysts set for ABLX?

4 brokerages have issued 1-year price targets for Ablynx's shares. Their predictions range from $25.00 to $33.00. On average, they expect Ablynx's stock price to reach $28.50 in the next twelve months. View Analyst Ratings for Ablynx.

Who are some of Ablynx's key competitors?

Who are Ablynx's key executives?

Ablynx's management team includes the folowing people:
  • Dr. Edwin Moses, Chief Exec. Officer and Director (Age 64)
  • Mr. Wim Ottevaere, Chief Financial Officer (Age 62)
  • Mr. Piet Houwen, Chief Operations Officer
  • Dr. Robert Friesen Ph.D., Chief Scientific Officer
  • Lies Vanneste, Director of Investor Relations

When did Ablynx IPO?

(ABLX) raised $151 million in an initial public offering on Wednesday, October 25th 2017. The company issued 7,200,000 shares at a price of $20.95 per share. BofA Merrill Lynch, J.P. Morgan and Jefferies served as the underwriters for the IPO and Baird, Bryan, Garnier and Ladenburg Thalmann were co-managers.

When did the company's lock-up period expire?

Ablynx's lock-up period expired on Monday, April 23rd. Ablynx had issued 11,430,000 shares in its IPO on October 25th. The total size of the offering was $200,025,000 based on an initial share price of $17.50. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.

Has Ablynx been receiving favorable news coverage?

Press coverage about ABLX stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ablynx earned a news impact score of 0.20 on Accern's scale. They also assigned press coverage about the company an impact score of 46.55 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Ablynx's major shareholders?

Ablynx's stock is owned by a number of of retail and institutional investors. Top institutional investors include Farallon Capital Management LLC (3.28%), Cowen Inc. (1.81%), Omni Partners LLP (0.55%), Eversept Partners LLC (0.24%), Longfellow Investment Management Co. LLC (0.17%) and Yakira Capital Management Inc. (0.08%). View Institutional Ownership Trends for Ablynx.

Which institutional investors are selling Ablynx stock?

ABLX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Ablynx.

Which institutional investors are buying Ablynx stock?

ABLX stock was purchased by a variety of institutional investors in the last quarter, including Cowen Inc., Omni Partners LLP, Longfellow Investment Management Co. LLC, Farallon Capital Management LLC, Eversept Partners LLC, Yakira Capital Management Inc., P Schoenfeld Asset Management LP and Kite Lake Capital Management UK LLP. View Insider Buying and Selling for Ablynx.

How do I buy shares of Ablynx?

Shares of ABLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ablynx's stock price today?

One share of ABLX stock can currently be purchased for approximately $52.89.

How big of a company is Ablynx?

Ablynx has a market capitalization of $4.07 billion.


MarketBeat Community Rating for Ablynx (ABLX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  49 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  104
MarketBeat's community ratings are surveys of what our community members think about Ablynx and other stocks. Vote "Outperform" if you believe ABLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABLX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ablynx (NASDAQ:ABLX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Ablynx in the last 12 months. Their average twelve-month price target is $28.50, suggesting that the stock has a possible downside of 46.11%. The high price target for ABLX is $33.00 and the low price target for ABLX is $25.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.753.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $28.50$28.50$28.50$28.50
Price Target Upside: 46.11% downside46.93% downside46.93% downside34.82% upside

Ablynx (NASDAQ:ABLX) Consensus Price Target History

Price Target History for Ablynx (NASDAQ:ABLX)

Ablynx (NASDAQ:ABLX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/29/2018Robert W. BairdDowngradeOutperform ➝ Neutral$33.00MediumView Rating Details
11/20/2017Ladenburg ThalmannInitiated CoverageBuy ➝ Buy$30.00N/AView Rating Details
11/20/2017JPMorgan ChaseInitiated CoverageOverweight ➝ Overweight$25.00N/AView Rating Details
11/10/2017Bank of AmericaInitiated CoverageBuy ➝ Buy$26.00N/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Dividends

Ablynx (NASDAQ:ABLX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ablynx (NASDAQ ABLX) Insider Trading and Institutional Ownership History

Insider Trading History for Ablynx (NASDAQ:ABLX)
Insider Trading History for Ablynx (NASDAQ:ABLX)

Ablynx (NASDAQ ABLX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Ablynx (NASDAQ ABLX) News Headlines

Source:
DateHeadline
ABLYNX COMPLETES PATIENT RECRUITMENT IN THE PHASE IIb RESPIRE STUDY OF ITS INHALED ANTI-RSV NANOBODY ALX-0171ABLYNX COMPLETES PATIENT RECRUITMENT IN THE PHASE IIb RESPIRE STUDY OF ITS INHALED ANTI-RSV NANOBODY ALX-0171
www.benzinga.com - April 30 at 9:54 AM
Who Are The Major Shareholders Of Ablynx NV (EBR:ABLX)?Who Are The Major Shareholders Of Ablynx NV (EBR:ABLX)?
finance.yahoo.com - April 30 at 9:54 AM
How Ablynx NV (EBR:ABLX) Can Impact Your Portfolio VolatilityHow Ablynx NV (EBR:ABLX) Can Impact Your Portfolio Volatility
finance.yahoo.com - April 23 at 9:24 AM
Ablynxs Lock-Up Period Set To Expire  on April 23rd (NASDAQ:ABLX)Ablynx's Lock-Up Period Set To Expire on April 23rd (NASDAQ:ABLX)
www.americanbankingnews.com - April 16 at 1:14 AM
Ablynx NV (ABLX) Reports Tiop-Line Results from Phase 2 Study of VobarilizumabAblynx NV (ABLX) Reports Tiop-Line Results from Phase 2 Study of Vobarilizumab
www.streetinsider.com - March 26 at 4:09 PM
Drugmaker Novo Nordisk looks to former oil boss to energize M&ADrugmaker Novo Nordisk looks to former oil boss to energize M&A
www.reuters.com - March 22 at 9:57 AM
What Do Analysts Think About Ablynx NV’s (EBR:ABLX) Long Term Outlook?What Do Analysts Think About Ablynx NV’s (EBR:ABLX) Long Term Outlook?
finance.yahoo.com - March 16 at 10:02 AM
Does Ablynx NV’s (EBR:ABLX) Debt Level Pose A Problem?Does Ablynx NV’s (EBR:ABLX) Debt Level Pose A Problem?
finance.yahoo.com - March 9 at 10:21 AM
Ablynx: ABLYNX ANNOUNCES 2017 FULL YEAR RESULTSAblynx: ABLYNX ANNOUNCES 2017 FULL YEAR RESULTS
www.finanznachrichten.de - February 22 at 9:29 AM
Ablynx NV - American Depositary Shares (ABLX) Short Interest UpdateAblynx NV - American Depositary Shares (ABLX) Short Interest Update
www.americanbankingnews.com - February 11 at 1:52 AM
Ablynx NV - American Depositary Shares (ABLX) Cut to "Neutral" at Robert W. BairdAblynx NV - American Depositary Shares (ABLX) Cut to "Neutral" at Robert W. Baird
www.americanbankingnews.com - January 29 at 4:24 PM
Novo Nordisk Is Planning to Raise Bid for Belgian AblynxNovo Nordisk Is Planning to Raise Bid for Belgian Ablynx
www.bloomberg.com - January 26 at 4:35 PM
ETFs with exposure to Ablynx NV : December 18, 2017ETFs with exposure to Ablynx NV : December 18, 2017
finance.yahoo.com - December 18 at 6:32 PM
ABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL...ABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL...
www.benzinga.com - December 7 at 7:07 PM
ETFs with exposure to Ablynx NV : December 7, 2017ETFs with exposure to Ablynx NV : December 7, 2017
finance.yahoo.com - December 7 at 7:07 PM
Ablynx NVs (ABLX) Quiet Period To End  on December 4thAblynx NV's (ABLX) Quiet Period To End on December 4th
www.americanbankingnews.com - November 29 at 1:34 AM
Ablynx NV (ABLX) Says Results from Hercules Study of Caplacizumab Selected for Late-Breaker at ASHAblynx NV (ABLX) Says Results from Hercules Study of Caplacizumab Selected for Late-Breaker at ASH
www.streetinsider.com - November 21 at 9:00 PM
ETFs with exposure to Ablynx NV : November 21, 2017ETFs with exposure to Ablynx NV : November 21, 2017
finance.yahoo.com - November 21 at 3:58 PM
Ablynx NV (ABLX) Coverage Initiated at Robert W. BairdAblynx NV (ABLX) Coverage Initiated at Robert W. Baird
www.americanbankingnews.com - November 21 at 12:52 AM
Ablynx NV (ABLX) Now Covered by J P Morgan Chase & CoAblynx NV (ABLX) Now Covered by J P Morgan Chase & Co
www.americanbankingnews.com - November 20 at 8:52 PM
Ablynx NV (ABLX) Coverage Initiated by Analysts at Ladenburg Thalmann Financial ServicesAblynx NV (ABLX) Coverage Initiated by Analysts at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - November 20 at 1:32 PM
Ablynx NV :ABLX-US: Earnings Analysis: For the six months ended June 30, 2017 : November 9, 2017Ablynx NV :ABLX-US: Earnings Analysis: For the six months ended June 30, 2017 : November 9, 2017
finance.yahoo.com - November 20 at 10:57 AM
ETFs with exposure to Ablynx NV : November 10, 2017ETFs with exposure to Ablynx NV : November 10, 2017
finance.yahoo.com - November 20 at 10:57 AM
Bank of America Corporation Begins Coverage on Ablynx NV (ABLX)Bank of America Corporation Begins Coverage on Ablynx NV (ABLX)
www.americanbankingnews.com - November 12 at 1:48 PM
Ablynx NV (ABLX) Announces October 25th IPOAblynx NV (ABLX) Announces October 25th IPO
www.americanbankingnews.com - October 21 at 1:26 AM

SEC Filings

Ablynx (NASDAQ:ABLX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Ablynx (NASDAQ ABLX) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.